Skip to main content .


BARDA partners with MBio Diagnostics to develop an in vitro point-of-care serology test for the detection of human anti-SARS-CoV-2 antibodies from whole blood samples

BARDA Response

BARDA and MBio Diagnostics are committed to a public-private partnership to develop a test for COVID-19. The MBio COVID-19 Serology Test is a rapid point-of-care serology test being designed to provide results in 5 minutes. This is a multiplexed cartridge-based lateral flow test that looks for anti-SARS-CoV-2 antibodies from active or past infections and allows on-site screening of people in non-professional settings such as a drive-thru setting or a walk-up testing site. The test also can assist in immunity assessment while broadening testing options.

The rapid point-of-care serology test will use MBio’s LightDeck® platform, and detect IgG (found in the blood and formed after infection) and IgM (formed while the body fights a new infection). The new test will quantify total antibody reactivity to three individual SARS-CoV-2 antigens which could provide critical data to aid in COVID-19 immunity assessment.

This award is one component of BARDA’s rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.

About MBio Diagnostics: 
The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.

MBio Diagnostics provides rapid, on-the-spot testing solutions for our global commercial partners. Our portable LightDeck® platform delivers panels of lab quality results in minutes for critical applications in health care, veterinary, and environmental industries. About LightDeck® Technology MBio’s patented LightDeck® technology system translates laboratory assays into on the-spot, critical decisions in minutes. Our LightDeck® platform incorporates low cost, multiplexed cartridges with our fluorescent readers and intuitive software, with the ability to measure more than 50 analytes in a single cartridge. Our partners use LightDeck® technology to test key analytes across many applications for competitive advantages in the areas of quantitative sensitivity, multiplexing, and speed.

Last Updated: June 23, 2020

Website Refresh

www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov